Return
Biography
Michael A.

Prof. Michael A. Linden

Department of Lab Medicine and Pathology
University of Minnesota Medical Center, USA


Email: linde013@umn.edu


Qualifications

2010-2011  University of Washington Medical Center, WAHematopathology fellowship, USA
2006-2010 Combined Anatomic and Clinical Pathology residency training
1998-2006  M.N., M.D., Ph.D., (Medical Scientist Training Program)
1994-1998  M.N., B.A., in Biology (Summa Cum Laude), University of Minnesota, Minneapolis, Saint Mary’s University, USA
1990-1994  Memorial High School, Eau Claire, WI, Summa Cum Laude


Publications(Selected)

  1. Linden MA, Gopal A, and Edlefsen KL. Acute appendicitis in a man undergoing therapy for mantle cell lymphoma. Case Reports in Hematology (in press)
  2. Yan D, Wang P, Linden M, Knudsen B, and Randolph T. Automated quantification of immunohistochemical staining for improved tissue microarray image scoring by Tissue Array Co-Occurrence Matrix Analysis (TACOMA). Annals of Applied Statistics (in press)
  3. Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of an activated N-ras gene results in B- and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. Experimental Hematology (in press)
  4. Linden MA and Apple FS. Use of B-type natriuretic peptide testing in a community teaching hospital 4 years after implementation and agreement of results with discharge diagnoses. Clinical Chemistry. 2006 Apr; 52(4):767-8.
  5. Dunn T, Linden MA, Vercellotti GM, and Gruessner RWG. Factor V Leiden and hepatic artery thrombosis after liver transplantation. Clinical Transplantation. 2006 Jan; 20(1):132-5.
  6. Linden MA, Kirchhof N, Kvitrud M, and Van Ness BG. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in bcl-XL transgenic mice. Leukemia Research. 2005 Apr; 29(4):435-444.
  7. Cheung WC, Kim JS, Linden MA, Van Ness BG, Polakiewicz R, Janz S. Novel targeted deregulation of c-myc and bcl-XL causes plasma cell neoplasms in mice. J Clinical Investigation. 2004 Jun; 113(12):1763-73.
  8. Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 2004 Apr 1; 103(7):2779-86.
  9. Croonquist PA, Linden MA, Zhao F, Van Ness BG. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and co-culture with bone marrow stromal cells. Blood. 2003 Oct 1; 102(7): 2581-92.
  10. Liu X, Linden M, Van Ness B. Induced kappa receptor editing shows no allelic preference in a mouse pre-B cell line. J Immunol. 2000 Dec 15; 165(12): 7058-63.
  11. Linden MA, Ward J and Cherian S. The Hematopoietic System. In: Comparative Anatomy and Histology for the Translational Pathologist: A Mouse and Human Atlas, Dintzis S and Treuting P., ed. Elsevier Press, Maryland Heights, MO, 2011.
  12. MA Linden. Implementation of the PCA3 urine test: an additional tool to aid in prostate cancer diagnostic decisions. Academy of Clinical Laboratory Physicians and Scientists Annual Meeting, Nashville, TN, June 2010. Oral presentation.
  13. MA Linden. Kanadaptin, a recently discovered protein with transport functionality, is overexpressed in prostate carcinoma. Canary Foundation Early Detection Symposium, Palo Alto, CA, May 2009. Poster presentation.
  14. MA Linden. The histological phenotype of TMPRSS2-ERG gene fusion prostate cancer is unaltered by neoadjuvant treatment with the 5-alpha-reductase inhibitor dutasteride. American Society of Clinical Pathology, Baltimore, MD, October 2008. Poster presentation.
  15. MA Linden. The prognostic power of biomarker MTA-1 for recurrence/biochemical failure post-radical prostatectomy. Canary Foundation Early Detection Symposium, Palo Alto, CA, May 2008. Poster presentation.
  16. MA Linden. Targeted overexpression of mutant activated N-ras leads to aberrant plasma cell biology. American Society of Hematology, San Diego, CA, December 2004. Poster presentation.
  17. MA Linden. Novel targeted deregulation of bcl-XL and c-myc leads to accelerated plasma cell malignancies. American Society of Hematology, San Diego, CA, December 2003. Oral presentation.
  18. MA Linden. Targeted overexpression of bcl-XL: toward a genetically-induced model of multiple myeloma. Fund to Cure Myeloma Roundtable, New York, NY, October 2003. Oral presentation.
  19. MA Linden. Novel targeted deregulation of bcl-XL and c-myc leads to accelerated plasma cell malignancies. 18th Annual National MD/PhD Student Conference, Snowmass, CO, July 2003. Oral presentation.
  20. MA Linden. Novel targeted deregulation of bcl-XL and c-myc leads to accelerated plasma cell malignancies. International Workshop on Multiple Myeloma, Salamanca, Spain, May 2003. Poster presentation.
  21. MA Linden. Pronounced plasma cell disease in a bcl-XL transgenic mouse. American Society of Hematology, Philadelphia, PA, December 2002. Oral presentation.
  22. MA Linden. Gene profiling of IL-6 response and N-ras activating mutations in a myeloma cell line. American Society of Hematology, Orlando, FL, December 2001. Poster presentation.